HES Flare: GSK's Nucala Edges Forward
Marketing Submissions Expected In 2020
GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.
You may also be interested in...
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group of rare disorders which can cause progressive organ damage.